SCILEX HOLDING CO
SCLXNASDAQTrading Snapshot
- Day Range
- $4.38 – $4.47
- 52-Week Range
- $2.62 – $27.00
- Volume
- $2.00B
- Avg Volume
- $2.54B
- Shares Outstanding
- 8.5M
- Next Earnings
- Nov 18, 2026
Fundamentals Snapshot
- Annual Revenue
- $30M
- Last Q Revenue
- $8M
- P/E Ratio
- -0.1
- P/S Ratio
- 1.2x
- EPS (TTM)
- $-64.87
- Dividend Yield
- 0.00%
- Dilution (1yr)
- −0.4%
Why Investors Own SCLX
- ✓High-growth profile — revenue up -0.9% YoY with expanding US Equity exposure.
- ✓Healthy economics — 60% gross margin and 11% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
SCILEX HOLDING CO
SCLX
StockOtter · stockotter.spaceAbout SCILEX HOLDING CO
Scilex Holding Company is a biopharmaceutical enterprise that specializes in the development and market introduction of non-opioid therapies designed to alleviate both acute and chronic pain. Its primary marketed offering is ZTlido 1.8%, a topical prescription formulation of lidocaine specifically engineered to mitigate neuropathic discomfort associated with post-herpetic neuralgia, a condition characterized by persistent nerve pain following shingles. Beyond this, the company's development pipeline includes SP-102, a viscous gel corticosteroid for epidural administration, currently undergoing Phase III trials for lumbosacral radicular pain. Another candidate, SP-103, is progressing through Phase II trials for managing low back pain. Furthermore, SP-104, a novel, low-dose, delayed-release naltrexone hydrochloride formulation, has successfully concluded Phase I clinical testing for the treatment of fibromyalgia. Its corporate offices are situated in Palo Alto, California. Scilex Holding Company operates as a subsidiary of Sorrento Therapeutics, Inc.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
Iterum Therapeutics (NASDAQ:ITRM) vs. Scilex (NASDAQ:SCLX) Critical Review
Scilex (NASDAQ: SCLX - Get Free Report) and Iterum Therapeutics (NASDAQ: ITRM - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the
Head to Head Survey: Scilex (NASDAQ:SCLX) versus Incannex Healthcare (NASDAQ:IXHL)
Scilex (NASDAQ: SCLX - Get Free Report) and Incannex Healthcare (NASDAQ: IXHL - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the str
Semnur Pharmaceuticals, Inc. (“Semnur”), a Majority-Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), Announces Signing of Binding Term Sheet for Proposed $100 Million Strategic Investment from iHolding Group LLP
PALO ALTO, Calif., July 07, 2026 (GLOBE NEWSWIRE) -- Semnur Pharmaceuticals, Inc. (“Semnur” or the “Company”) (OTC: SMNR) , a clinical late-stage specialty pharmaceutical company focused on the development and commercial
Scilex Holding Company Announces Dream Bowl I Meme Coin Tokens Commence Trading on the Biconomy Exchange on July 6, 2026
PALO ALTO, Calif., July 06, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing, and commercializing non-o
Scilex Holding Company Announces Signing of Binding Term Sheet for Proposed $100 Million Strategic Investment from iHolding Group LLP
PALO ALTO, Calif., July 06, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing, and commercializing non-o